rx-10045
Small moleculeexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00799552)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Solute carrier family 22 member 1INHIBITOR
SLC22A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate
- rx-10045
- rx-10045
- rx-10045
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02329743 | Phase 2 | Dec 1, 2014 | A.T. Resolve SARL, Auven Therapeutics |
| NCT01675570 | Phase 2 | Aug 1, 2012 | Andover Eye Associates, C.T. Development America, Inc. |
| NCT01639846 | Phase 2 | Jul 1, 2012 | Andover Eye Associates, C.T. Development America, Inc. |
| NCT00799552 | Phase 2 | Nov 1, 2008 | Central Maine Eye Care, ORA, Inc., Resolvyx Pharmaceuticals, Inc, The Eye Care Group, Waterbury, CT |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Andover Eye Associates | Academic/Hospital | 2 | 0 | 1 | 2012 |
| C.T. Development America, Inc. | For profit | 2 | 2 | 1 | 2012 |
| A.T. Resolve SARL | For profit | 1 | 1 | 1 | 2014 |
| Auven Therapeutics | For profit | 1 | 0 | 1 | 2014 |
| Central Maine Eye Care | Academic/Hospital | 1 | 0 | 1 | 2008 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2008 |
| Resolvyx Pharmaceuticals, Inc | For profit | 1 | 1 | 1 | 2008 |
| The Eye Care Group, Waterbury, CT | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1